

1262725

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

December 16, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/557,631

FILING DATE: *March 30, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US04/36551

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office





0990 US PTO

PTO/SB/16 (01-04)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 383801787

U.S.PTO
29154
601557631

033004

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Jonathan J.	Duffield	San Diego, California

Additional inventors are being named on the _____ second separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)Direct all correspondence to: **CORRESPONDENCE ADDRESS**

Customer Number: 32301

OR

<input type="checkbox"/> Firm or Individual Name				
Address				
Address				
City	State		Zip	
Country	Telephone		Fax	

ENCLOSED APPLICATION PARTS (check all that apply)

- | | |
|--|--|
| <input checked="" type="checkbox"/> Specification Number of Pages 47 | <input type="checkbox"/> CD(s), Number _____ |
| <input type="checkbox"/> Drawing(s) Number of Sheets _____ | <input type="checkbox"/> Other (specify) _____ |
| <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 | |

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

- | | |
|---|---------------------------|
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. | FILING FEE
Amount (\$) |
| <input type="checkbox"/> A check or money order is enclosed to cover the filing fees. | |
| <input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 502235 | 80.00 |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. | |

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

 No. Yes, the name of the U.S. Government agency and the Government contract number are: _____

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Thomas E. Jurgensen, Esq.

Date March 30, 2004

REGISTRATION NO. 34,195

(if appropriate)

Docket Number. 8024-012-PR2

TELEPHONE (858) 450-0099

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (02-01)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Docket Number	8024-012-PR2
--	---------------	--------------

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Kenneth	Marby	San Diego, California
Sean M.	O'Hare	San Diego, California
Chan-Kou	Hwang	San Diego, California
Yoshitaka	Ichikawa	San Diego, California

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

05990
023004

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. PTO

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 80.00)

Complete if Known

Application Number	
Filing Date	March 30, 2004
First Named Inventor	Jonathan J. Duffield
Examiner Name	
Art Unit	
Attorney Docket No.	8024-002-PR2

METHOD OF PAYMENT (check all that apply)

Check Credit card Money Order Other None

Deposit Account:

Deposit Account Number	502235
Deposit Account Name	

The Director is authorized to: (check all that apply)

- Charge fee(s) indicated below Credit any overpayments
- Charge any additional fee(s) or any underpayment of fee(s)
- Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	80.00
SUBTOTAL (1)		(\$ 80.00)	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Independent Claims	Multiple Dependent	Extra Claims	Fee from below	Fee Paid
			-20** =	X	=
			- 3** =	X	=

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$)

**or number previously paid, if greater. For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	
Other fee (specify)			
*Reduced by Basic Filing Fee Paid			
SUBTOTAL (3)		(\$)	

(Complete if applicable)

Name (Print/Type)	Thomas E. Jurgenssen, Esq.	Registration No. (Attorney/Agent)	34,195	Telephone	858-450-0099
Signature				Date	March 30, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

March 30, 2004

EV383801787US

Certificate of Express Mail Mailing

Under 37 CFR 1.10 I certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EV 383801787 US in an envelope addressed to: Assistant Commissioner of Patents, Box Provisional Patent Application, P. O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:


Shar Dirkovich

March 30, 2004
Date of Deposit

Mail Stop: PROVISIONAL PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


**Re: SYNTHESIS OF GLYCOPEPTIDES WITH SUPERIOR PHARMACOKINETIC
PROPERTIES**
Our Docket No.: 8024-012-PR2

Dear Sir or Madam:

Enclosed please find the following documents related to the above-identified matter:

1. Provisional Application for Patent Cover Sheet (PTO/SB/16);
2. Fee Transmittal (PTO/SB/17);
3. Specification/claims; and
4. Self-addressed, stamped postcard.

The self-addressed, stamped postcard has been included for your convenience. After confirming receipt of these documents please return the postcard to us at your earliest convenience. Should you have any questions, please do not hesitate to contact me by phone at (858) 450-0099.


Sincerely yours,
Thomas E. Jurgensen
Reg. No. 34,195

Enclosures

Date: March 30, 2004

Express Mail Label No.: EV383801787 US

Inventors: Jonathan Duffield, Kenneth Marby, Sean O'Hare, Chan-Kou Hwang,
Yoshitaka Ichikawa

5

**SYNTHESIS OF GLYCOPEPTIDES WITH SUPERIOR
PHARMACOKINETIC PROPERTIES**

RELATED APPLICATIONS

The present application is related to, and claims priority from, United States
10 Provisional Patent Application No. 60/516,838, filed November 4, 2003, the entire
disclosure of which is herein incorporated by reference.

FIELD OF INVENTION

The present invention relates generally to novel glycopeptides having
15 improved pharmacokinetic properties, methods of producing the same, and methods
of using the same.

BACKGROUND OF THE INVENTION

Carbohydrates play important roles in biological processes and the
20 saccharide motifs of glycopeptides and glycoproteins are critical determinants of
conformational and physicochemical properties. The number of peptide-based
drugs and clinical candidates in the field of medicine is growing steadily, with new
applications emerging in cardiovascular disease, metabolic disorders, cancer, anti-
bacterial, and anti-viral therapeutic areas among many others. But the potential of
25 peptides as therapeutic agents is limited by their significant instability in the
presence of peptidase enzymes, which drastically reduces the drugs' half-lives *in*
vivo. There are only limited synthetic approaches with which it is possible to modify
the pharmacokinetic properties of peptides, typically using preassembled, protected
glycosyl-amino acids via solid-phase peptide synthesis (Powell, M. F. et al., *Pharm.*
30 *Res.* 1993, 10, 1268-1273), (Polt, R. J. *J. Am. Chem. Soc.* 2003, 125, 5823-5831). To

date, the prior art does not provide for a method to effectively address this significant need. The present invention provides for a solution to meet this and other needs.

SUMMARY OF THE INVENTION

5 The present invention relates to novel glycopeptides, methods for preparing novel glycopeptides, and for using said novel glycopeptides to enhance the stability of a peptide towards peptidase enzymes. Unlike the prior art, the present invention provides for the conjugation of carbohydrates with native peptides and peptide surrogates. Therefore, the present invention advantageously confers highly
10 desirable drug-like properties upon the resulting glycoconjugate.

DETAILED DESCRIPTION OF THE INVENTION

The present invention generally relates to a novel methodology for the addition of one or more carbohydrate moieties to peptides through a linker or spacer
15 or directly without such a linker or spacer between the anomeric position of the carbohydrate and an amino, hydroxyl or carboxyl group on the peptide, thereby significantly increasing the half-life of said peptide in a biological system.

Definitions

20 The compounds of the invention comprise asymmetrically substituted carbon atoms. Such asymmetrically substituted carbon atoms can result in the compounds of the invention comprising mixtures of stereoisomers at a particular asymmetrically substituted carbon atom or a single stereoisomer. As a result, racemic mixtures, mixtures of diastereomers, as well as single diastereomers of the compounds of the
25 invention are included in the present invention. The terms "S" and "R" configuration, as used herein, are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-30.

30 The compositions containing the compound(s) of the invention can be administered for prophylactic and/or therapeutic treatments. An amount adequate to accomplish this is defined as "therapeutically effective amount or dose." Amounts effective for this use will depend on the severity and course of the disease or

condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician. In prophylactic applications, compositions containing the compounds of the invention are administered to a patient susceptible to or otherwise at risk of a particular disease or condition. Such
5 an amount is defined to be a "prophylactically effective amount or dose." In this use, the precise amounts again depend on the patient's state of health, weight, and the like.

Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of
10 administration, or both, can be reduced, as a function of the symptoms, to a level at which the improved condition is retained. When the symptoms have been alleviated to the desired level, treatment can cease. Patients can, however, require intermittent treatment on a long-term basis upon any recurrence of the disease symptoms.

In general, a suitable effective dose of the compound of the invention will be
15 in the range of 0.1 to 1000 milligrams (mg) per recipient per day, preferably in the range of 1 to 100 mg per day. The desired dosage is preferably presented in one, two, three, four or more subdoses administered at appropriate intervals throughout the day. These subdoses can be administered as unit dosage forms, for example, containing 5 to 1000 mg, preferably 10 to 100 mg of active ingredient per unit
20 dosage form. Preferably, the compounds of the invention will be administered in amounts of between about 1.0 mg/kg to 250 mg/kg of patient body weight, between about one to four times per day.

A "pharmacological composition" refers to a mixture of one or more of the compounds described herein, or physiologically acceptable salts thereof, with other
25 chemical components, such as physiologically acceptable carriers and/or excipients. The purpose of a pharmacological composition is to facilitate administration of a compound to an organism.

The term "pharmaceutically acceptable salts" of the compounds of the invention include those derived from pharmaceutically acceptable inorganic and
30 organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic,

gluconic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic, 1,2 ethanesulfonic acid (edisylate), galactosyl-D-gluconic acid, and the like. Other acids, such as oxalic acid, while not themselves pharmaceutically acceptable, may
5 be employed in the preparation of salts useful as intermediates in obtaining the compounds of this invention and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N(C₁-C₄)₄⁺ salts, and the like. Illustrative examples of some of these include sodium hydroxide, potassium
10 hydroxide, choline hydroxide, sodium carbonate, and the like.

The term "carbon chain" may embrace any alkyl, alkenyl, alkynyl, or heteroalkyl, heteroalkenyl, or heteroalkynyl group, and may be linear, cyclic, or any combination thereof. If part of a linker and that linker comprises one or more rings as part of the core backbone, for purposes of calculating chain length, the "chain"
15 only includes those carbon atoms that compose the bottom or top of a given ring and not both, and where the top and bottom of the ring(s) are not equivalent in length, the shorter distance shall be used in determining chain length. If the chain contains heteroatoms as part of the backbone, those atoms are not calculated as part of the carbon chain length.

20 The term "physiologically acceptable carrier" refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.

The term "excipient" refers to an inert substance added to a pharmacological composition to further facilitate administration of a compound. Examples of
25 excipients include but are not limited to, calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

30 The term "alkyl", alone or in combination, refers to an optionally substituted straight-chain, optionally substituted branched-chain, or optionally substituted cyclic alkyl radical having from 1 to about 30 carbons, preferably 1 to 12 carbons.

Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, tert-amyl, pentyl, hexyl, heptyl, octyl and the like.

The term "cycloalkyl" embraces cyclic configurations, is subsumed within the definition of alkyl and specifically refers to a monocyclic, bicyclic, tricyclic, and higher multicyclic alkyl radicals wherein each cyclic moiety has from 3 to about 8 carbon atoms. Examples of cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. A "lower alkyl" is a shorter alkyl, e.g., one containing from 1 to about 6 carbon atoms.

The term "alkenyl," alone or in combination, refers to an optionally substituted straight-chain, optionally substituted branched-chain, or optionally substituted cyclic alkenyl hydrocarbon radical having one or more carbon-carbon double-bonds and having from 2 to about 30 carbon atoms, more preferably 2 to about 18 carbons. Examples of alkenyl radicals include ethenyl, propenyl, butenyl, 1,4-butadienyl and the like. The term can also embrace cyclic alkenyl structures.

The term "lower alkenyl" refers to an alkenyl having from 2 to about 6 carbons. The term "alkynyl," alone or in combination, refers to an optionally substituted straight-chain, optionally substituted branched-chain, or cyclic alkynyl hydrocarbon radical having one or more carbon-carbon triple-bonds and having from 2 to about 30 carbon atoms, more preferably 2 to about 12 carbon atoms. The term also includes optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon radicals having one or more carbon-carbon triple bonds and having from 2 to about 6 carbon atoms as well as those having from 2 to about 4 carbon atoms. Examples of alkynyl radicals include ethynyl, propynyl, butynyl and the like.

The terms heteroalkyl, heteroalkenyl and heteroalkynyl include optionally substituted alkyl, alkenyl and alkynyl structures, as described above, and which have one or more skeletal chain atoms selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorous or combinations thereof.

The term "alkoxy," alone or in combination, refers to an alkyl ether radical, alkyl-O-, wherein the term alkyl is defined as above. Examples of alkoxy radicals

include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.

The term "aryloxy," alone or in combination, refers to an aryl ether radical wherein the term aryl is defined as below. Examples of aryloxy radicals include
5 · phenoxy, benzyloxy and the like.

The term "alkylthio," alone or in combination, refers to an alkyl thio radical, alkyl-S-, wherein the term alkyl is defined as above.

The term "arylthio," alone or in combination, refers to an aryl thio radical, aryl-S-, wherein the term aryl is defined as below.

10 The term "aryl," alone or in combination, refers to an optionally substituted aromatic ring system. The term aryl includes monocyclic aromatic rings, polycyclic aromatic rings and polycyclic aromatic ring systems containing from six to about twenty carbon atoms. The term aryl also includes monocyclic aromatic rings, polycyclic aromatic rings and polycyclic ring systems containing from 6 to about 12 carbon
15 atoms, as well as those containing from 6 to about 10 carbon atoms. The polycyclic and polycyclic aromatic rings systems may contain from two to four rings. Examples of aryl groups include, without limitation, phenyl, biphenyl, naphthyl and anthryl ring systems.

20 The term "heteroaryl" refers to optionally substituted aromatic ring systems containing from about five to about 20 skeletal ring atoms and having one or more heteroatoms such as, for example, oxygen, nitrogen, sulfur, and phosphorus. The term heteroaryl also includes optionally substituted aromatic ring systems having from 5 to about 12 skeletal ring atoms, as well as those having from 5 to about 10 skeletal ring atoms. The term heteroaryl may include five- or six-membered
25 heterocyclic rings, polycyclic heteroaromatic ring systems and polyheteroaromatic ring systems where the ring system has two, three or four rings. The terms heterocyclic, polycyclic heteroaromatic and polyheteroaromatic include ring systems containing optionally substituted heteroaromatic rings having more than one heteroatom as described above (e.g., a six membered ring with two nitrogens),
30 including polyheterocyclic ring systems of from two to four rings. The term heteroaryl includes ring systems such as, for example, furanyl, benzofuranyl,

chromenyl, pyridyl, pyrrolyl, indolyl, quinolinyl, *N*-alkyl pyrrolyl, pyridyl-*N*-oxide, pyrimidoyl, pyrazinyl, imidazolyl, pyrazolyl, oxazolyl, benzothiophenyl, purinyl, indolizinyl, thienyl and the like.

The term "heteroarylalkyl" refers to a C1-C4 alkyl group containing a


5 heteroaryl group, each of which may be optionally substituted.

The term "heteroarylthio" refers to the group -S-heteroaryl.

The term "acyloxy" refers to the ester group -OC(O)-R, where R is H, alkyl, alkenyl, alkynyl, aryl, or arylalkyl, wherein the alkyl, alkenyl, alkynyl and arylalkyl groups may be optionally substituted.

10 The term "carboxy esters" refers to -C(O)OR where R is alkyl, aryl or arylalkyl, wherein the alkyl, aryl and arylalkyl groups may be optionally substituted.

The term "carboxamido" refers to:



wherein each of R and R' are independently selected from the group consisting of H,

15 alkyl, aryl and arylalkyl, wherein the alkyl, aryl and arylalkyl groups may be optionally substituted.

The term "arylalkyl," alone or in combination, refers to an alkyl radical as defined above in which one H atom is replaced by an aryl radical as defined above, such as, for example, benzyl, 2-phenylethyl and the like.

20 The terms "haloalkyl", "haloalkenyl", "haloalkynyl" and "haloalkoxy" include alkyl, alkenyl, alkynyl and alkoxy structures, as described above, that are substituted with one or more fluorines, chlorines, bromines or iodines, or with combinations thereof.

The terms "cycloalkyl", "aryl", "arylalkyl", "heteroaryl", "alkyl", "alkynyl", 25 "alkenyl", "haloalkyl" and "heteroalkyl" include optionally substituted cycloalkyl, aryl, arylalkyl, heteroaryl, alkyl, alkynyl, alkenyl, haloalkyl and heteroalkyl groups.

The term "carbocycle" includes optionally substituted, saturated or unsaturated, three- to eight-membered cyclic structures in which all of the skeletal atoms are carbon.

The term "membered ring" can embrace any cyclic structure, including carbocycles and heterocycles as described above. The term "membered" is meant to denote the number of skeletal atoms that constitute the ring. Thus, for example, pyridine, pyran, and thiopyran are 6-membered rings and pyrrole, furan, and

5 thiophene are 5-membered rings.

The term "acyl" includes alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl substituents attached to a compound via a carbonyl functionality (e.g., -CO-alkyl, -CO-aryl, -CO-arylalkyl or -CO-heteroarylalkyl, etc.).

10 The term "alkylacylamino" as used herein refers to an alkyl radical appended to an acylamino group.

The term "acylamino" as used herein refers to an acyl radical appended to an amino group.













15 The term "substituted heterocycle" or heterocyclic group" as used herein refers to any 3-, or 4-membered ring containing a heteroatom selected from nitrogen, oxygen, phosphorus and sulfur or a 5- or 6-membered ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus and sulfur; wherein the 5-membered ring has 0-2 double bounds and the 6-membered ring has 0-3 double bounds; wherein the nitrogen and sulfur atom maybe optionally oxidized; wherein the nitrogen heteroatoms maybe optionally
20 quaternized; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another 5- or 6-membered heterocyclic ring independently defined above. Heterocyclics can be unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (C=O), alkylimino (R-N= wherein R is a alkyl group), amino,
25 alkylamino, dialkylamino, acylaminoalkyl, alkoxy, thioalkoxy, polyalkoxy, alkyl, cycloalkyl or haloalkyl. Examples of heterocyclics include: imidazolyl, pyridyl, piperazinyl, azetidinyl, thiazolyl and triazolyl.

30 The term "glycosyl" as used herein refers to any pyranose or furanose saccharide group, including but not limited to D- or L-glucosyl, galactosyl,mannosyl, fucosyl, N-acetylneuraminy, glucosaminyl, galactosaminyl, etc.








The term "disaccharide" as used herein refers to any pyranose or furanose saccharide group, including but not limited to D- or L-glucosyl, galactosyl, mannosyl, fucosyl, N-acetylneuraminyl, glucosaminyl, galactosaminyl, etc. linked through a glycosidic bond to any other another pyranose or furanose saccharide.


- 5 The term "oligosaccharide" as used herein refers to any pyranose or furanose groups including but not limited to D- or L-glucosyl, galactosyl, mannosyl, fucosyl, N-acetylneuraminyl, glucosaminyl, galactosaminyl, etc. linked through glycosidic bonds to any other another pyranose or furanose saccharides in which the number of saccharide groups is no less than three.
- 10 The term "glycosyl donor" as used herein refers to any pyranose or furanose saccharide or disaccharide group capable of glycosylating an acceptor such as hydroxyl, donors and includes but is not limited to suitably protected D- or L-thiotolyl glucopyranoside, thiotolyl galactopyranoside, mannopyranoside, fucopyranoside, N-acetylneuraminopyranoside, glucosaminopyranoside,
- 15 galactosaminopyranoside, etc. The glycosidic linkages can be alpha, beta or alpha/beta mixtures. The following are examples of such saccharide and disaccharide groups:

Group A Epitopes















Group B Eptiopes






Group C Eptiopes



Group D Epitopes



The term "carbohydrate-activating group" as used herein refers to classes of functional groups that when attached to carbohydrates convert them into glycosyl donors. The carbohydrate-activating group is generally located at the anomeric position of the carbohydrate. Activating groups based on the type of anomeric

- 5 functional group and their activating methods include but are not limited to: glycosyl halides, thioglycosides, 1-O-Acyl sugars, 1-O- and S-carbonates, trichloroimidates, etc.

The term "saccharide group" refers to an oxidized, reduced or substituted saccharide monoradical covalently attached via any atom of the saccharide moiety,

- 10 preferably via the anomeric carbon atom. A saccharide refers to a carbohydrate which is a polyhydroxy aldehyde or ketone, or derivative thereof, having the empirical formula $(CH_2O)_n$ wherein n is a whole integer, typically greater than 3. Monosaccharides, or simple sugars, consist of a single polyhydroxy aldehyde or ketone unit. Representative monosaccharides include, by way of illustration only,
15 hexoses such as D-glucose, D-mannose, D-xylose, D-galactose, L-fucose, and the like; pentoses such as D-ribose or D-arabinose and ketoses such as D-ribulose or D-fructose. Disaccharides contain two monosaccharide units joined by a glycosidic linkage. Disaccharides include, for example, sucrose, lactose, maltose, cellobiose, and the like. Oligosaccharides typically contain from 3 to 10 monosaccharide units
20 joined by glycosidic linkages. Polysaccharides (glycans) typically contain more than 10 such units and include, but are not limited to, molecules such as heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate and polysaccharide derivatives thereof.

The term "sugar" generally refers to mono-, di- or oligosaccharides. A

- 25 saccharide may be substituted, for example, glucosamine, galactosamine, acetylglucosamine, acetylgalactose, N-acetylglucosamine, N-acetyl-galactosamine, galactosyl-N-acetylglucosamine, N-acetylneuraminic acid (sialic acid), etc., and may contain sulfated and phosphorylated sugars. For the purposes of this definition, the saccharides can be either in their open or preferably in their pyranose form.

- 30 The term "amino-containing saccharide group" refers to a saccharide group having at least one amino substituent. Representative amino-containing saccharides

include mycaminose, desosamine, L-vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-dau nosamine, ristosamine, N-methyl-D-glucamine and the like.

"Optionally substituted" groups may be substituted or unsubstituted. The substituents of an "optionally substituted" group may include, without limitation, one or more substituents independently selected from the following groups or designated subsets thereof: alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy, haloalkoxy, amino, alkylamino, dialkylamino, alkylthio, arylthio, heteroarylthio, oxo, carboxyesters, carboxamido, acyloxy, H, F, Cl, Br, I, CN, NO₂, NH₂, N₃, NHCH₃, N(CH₃)₂, SH, SCH₃, OH, OCH₃, OCF₃, CH₃, CF₃, C(O)CH₃, CO₂CH₃, CO₂H, C(O)NH₂, pyridinyl, thiophene, furanyl, indole, indazol, esters, amides, phosphonates, phosphates, phosphoramides, sulfonates, sulfates, sulfonamides, carbamates, ureas, thioureas, thioamides, thioalkyls. An optionally substituted group may be unsubstituted (e.g., -CH₂CH₃), fully substituted (e.g., -CF₂CF₃), monosubstituted (e.g., -CH₂CH₂F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., -CH₂CF₃).

The term "halogen" includes F, Cl, Br and I.

The term "protected amino", "amine protecting group" and "protected aminomethyl" as used herein refers to known amine protecting groups used in the synthetic organic chemistry art and include but are not limited to *t*-butoxycarbonyl (BOC), benzyloxycarbonyl (Cbz), azide (N₃), 2-trimethylsilylethoxycarbonyl (Teoc), allyloxycarbonyl (Alloc), 9-fluorenylmethyloxycarbonyl (Fmoc), acyl groups, such as formyl, acetyl, trihaloacetyl, benzoyl, and nitrophenylacetyl, sulfonamide groups, imine- and cyclic imide groups. Further examples of protected amino groups are described by Greene and Wuts in Protective Groups in Organic Synthesis, 2nd edition (John Wiley & Sons, New York, 1991).


The term "modified amino" as used herein includes the terms "protected amino," "amine protecting group," "alkylacylamino," "acylamino" and "carboxamido".

The term "modified hydroxyl" as used herein includes the terms "protected hydroxyl", "hydroxyl protecting group", "protected hydroxymethyl," "alkoxy," "aryloxy," "acyl," "carboxy esters," and "acyloxy"

- 5 The term "protected hydroxyl", "hydroxyl protecting group" and "protected hydroxymethyl" as used herein refers to known hydroxyl protecting groups used in the synthetic organic chemistry art and include but are not limited to methoxymethyl (MOM), benzyloxymethyl (BOM), benzyl (Bn), Allyl (All), *p*-methoxybenzyl (PMB), *t*-butyldimethylsilyl (TBDMS), ester groups, such as, acetate (Ac), and chloroacetate and benzoate (Bz). Further examples of protected hydroxyl groups are described by
- 10 Greene and Wuts in Protective Groups in Organic Synthesis, 2nd edition (John Wiley & Sons, New York, 1991).

- In accordance with the present invention, conjugation is achieved in one of three different ways. First, conjugation is achieved through a linker attached at the anomeric position of suitably protected or unprotected carbohydrate residues and terminating in a carboxylic acid function. Second, conjugation is achieved through a linker attached at the anomeric position of such carbohydrate residues terminating in an amino function. Or third, conjugation is achieved through a direct glycosylation reaction at the anomeric position of such a carbohydrate moiety in which the anomeric position is suitably activated.

- 20 In a preferred embodiment of the present invention, the carbohydrate can be coupled to a suitably protected peptide *via* a dehydration reaction at the α -amino terminus thus:



where R₁ is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination and in which any hydroxyl, amino or carboxyl functions are suitably modified by sulfation, alkylation, acylation, deoxygenation, 5 diazotization, silylation and the like;


R₂ is the atom or group at the anomeric position of the carbohydrate R₁ and may be O, S, NH or CH₂;

R₃ is a linker composed of alone or in any combination alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, 10 heteroaryl, heteroarylalkyl, heteroarylthio, acyloxy, carboxyesters, carboxamido, arylalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, cycloalkyl, acyl, alkylacylamino or acylamino groups or amino acid residues;

R₄ and R₅, when substituted with NH₂ and CO₂H, are any natural amino acid or amino acid surrogate in which any reactive groups are suitably protected;

15 and n is any integer from 1 to about 100, but may be greater.

In another preferred embodiment of the present invention, one or more protected carbohydrates are conjugated through a linker to hydroxyl or amine functions on the side chains of amino acids along the backbone of a suitably protected peptide via a dehydration reaction thus:



20

where R₁ is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination and in which any hydroxyl, amino or carboxyl

functions are suitably modified by sulfation, alkylation, acylation, deoxygenation, diazotization, silylation and the like;

R_2 is the atom or group at the anomeric position of the carbohydrate R_1 and may be O, S, NH or CH_2 ;

- 5 R₃ is a linker composed of alone or in any combination alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, heteroaryl, heteroarylalkyl, heteroarylthio, acyloxy, carboxyesters, carboxamido, arylalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, cycloalkyl, acyl, alkylacylamino or acylamino groups or amino acid residues;


- 10 R₆ is a protecting group for an amine including but not limited to Fmoc, Boc, Cbz and the like;

R₇, when substituted with NH₂ and CO₂H, is any suitably protected natural or synthetic peptide containing one or more amino acid residues with side chains bearing a hydroxyl or amine function such as serine, threonine, hydroxyproline,

- 15 tyrosine, lysine, hydroxylysine, arginine, or any other amino acid surrogates containing a hydroxyl or amine function on the side chain:

and n , is any integer from 1 to about 100, but may be greater.

In another preferred embodiment of the present invention, the carbohydrate can be coupled to a suitably protected peptide via a dehydration reaction at the α -carboxyl terminus thus:



where R₁ is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination and in which any hydroxyl, amino or carboxyl

functions are suitably modified by sulfation, alkylation, acylation, deoxygenation, diazotization, silylation and the like;

R₂ is the atom or group at the anomeric position of the carbohydrate R₁ and may be O, S, NH or CH₂;


5 R₃ is a linker composed of alone or in any combination alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, heteroaryl, heteroarylalkyl, heteroarylthio, acyloxy, carboxyesters, carboxamido, arylalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, cycloalkyl, acyl, alkylacylamino or acylamino groups or amino acid residues;

10 R₄ and R₅, when substituted with NH₂ and CO₂H, are any natural amino acid or amino acid surrogate in which any reactive groups are suitably protected;

 R₆ is a protecting group for an amine including but not limited to Fmoc, Boc, Cbz and the like;

 and n is any integer from 1 to about 100, but may be greater.

15 In another preferred embodiment of the present invention, one or more protected carbohydrates are conjugated through a linker to carboxyl functions on the side chains of amino acids along the backbone of a suitably protected peptide via a dehydration reaction thus:



20 where R₁ is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination and in which any hydroxyl, amino or carboxyl

functions are suitably modified by sulfation, alkylation, acylation, deoxygenation, diazotization, silylation and the like;

R₂ is the atom or group at the anomeric position of the carbohydrate R₁ and may be O, S, NH or CH₂;

5 R₃ is a linker composed of alone or in any combination alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, heteroaryl, heteroarylalkyl, heteroarylthio, acyloxy, carboxyesters, carboxamido, arylalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, cycloalkyl, acyl, alkylacylamino or acylamino groups or amino acid residues;



10 R₆ is a protecting group for an amine including but not limited to Fmoc, Boc, Cbz and the like;

15 R₇, when substituted with NH₂ and CO₂H, is any suitably protected natural or synthetic peptide containing one or more amino acid residues with side chains bearing a carboxyl function such as aspartic acid or glutamic acid, or any other amino acid surrogates containing a carboxyl function on the side chain;

R₈ is a protecting group for a carboxylic acid including but not limited to methyl, ethyl, t-butyl, allyl, benzyl, succinyl, trimethylsilylethyl, p-nitrophenyl, pentafluorophenyl, and the like;

and n is any integer from 1 to about 100, but may be greater.

20 In another preferred embodiment of the present invention, a protected carbohydrate is conjugated to a hydroxy or amino group on the side chain of an amino acid along the backbone of a suitably protected peptide via direct glycosylation thus:



where R₁ is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination and in which any hydroxyl, amino or carboxyl functions are suitably modified by sulfation, alkylation, acylation, deoxygenation, diazotization, silylation and the like;

R₆ is a protecting group for an amine including but not limited to Fmoc, Boc, Cbz and the like;

R₇, when substituted with NH₂ and CO₂H, is any suitably protected natural or synthetic peptide containing one or more amino acid residues with side chains bearing a hydroxyl or amine function such as serine, threonine, hydroxyproline, tyrosine, lysine, hydroxylysine, arginine, or any other amino acid surrogates containing a hydroxyl or amine function on the side chain;

R₉ is a sugar activating group such as but not limited to sulfide, trichloroacetimidate, bromide, chloride, fluoride, acyloxy, sulfoxide, phosphite and the like;

and n is any integer from 1 to about 100, but may be greater.

Thus, with respect to the above described preferred embodiments, the present invention encompasses both the method of making such glycoconjugates as well as the resulting glycoconjugate compounds and compositions.

Methods

Carbohydrates including mono-, di-, tri- and tetrasaccharides and larger are prepared using OPopS™ technology (WO000/09527) in a one-pot fashion in which the final acceptor contains a carboxylic ester or a protected amine. Following this glycosylation step the protecting group can be removed allowing for coupling to the peptide. Those of skill in the art recognize that the present invention is not limited by these coupling methods. Rather, those of skill in the art recognize that the present invention includes other available coupling methods.

For example, for direct attachment of a sugar motif to a hydroxyl group of the peptide through its anomeric position, the sugar donor portion may have an

anomeric activating group including but not limited to alkyl or aryl thio, halide (Br, Cl, F), trialkyl or triaryl phosphate, dialkyl or diaryl phosphite, imidate (trichloroacetimidate), OH, or O-acyl group. An activating reagent can be used to promote the condensation reaction between the sugar donor and the peptide

- 5 acceptor, and the reagents include but are not limited to Lewis acids (trialkylsilyl triflate, boron trifluoride-etherate), methyl triflate, dimethyl(methylthio)sulfonium triflate, *N*-iodosuccinimide (NIS), *N*-bromosuccinimide (NBS), NIS/trifluoromethanesulfonic acid (triflic acid), NBS/triflic acid, NIS/trialkylsilyl triflate, NBS/trialkylsilyl triflate, NIS/tetraalkylammonium trifluoromethansulfonate, ,
10 NBS/tetraalkylammonium trifluoromethansulfonate, 1-benzenesulfinyl piperidine/triflic anhydride and NIS(trimethylsilyl triflate, SnCl₂/AgClO₄, SnCl₂/TrClO₄, SnCl₂/AgOTf, TMSOTf, SiF₄, Cp₂MCl₂/AgClO₄ (M = Zr or Hf), Cp₂ZrCl₂/AgBF₄, Cp₂HfCl₂/AgOTf, Yb(OTf)₃, La(ClO₄)₃, La(ClO₄)₃/Sn(OTf)₂, Nafion-H, montmorillonite K-10, and TrB(C₆F₅)₄. (References: Toshima, K.; Tatsuta, K. *Chemical Review*,
15 1993, 93, 1503-1531; Boons, G.-J. *Tetrahedron*, 1996, 52, 1095-1121; Garegg, P. J. *Adv. Carbohydr. Chem. Biochem.* 1997, 52, 179-205; Toshima, K. *Carbohydr. Res.* 2000, 327, 15-26).

- The peptide can be prepared using solid phase synthesis techniques (Merrifield, R. B., *J. Am. Chem. Soc.*, 1963, 85, 2149-2154) to give a molecule in which one or more amino, hydroxyl or carboxyl groups remain unprotected. These may be the N-terminal α -amine, the C-terminal α -carboxylic acid or amines, alcohols or carboxylic acids on side chains of amino acids, which may be serine, threonine, hydroxyproline, tyrosine, lysine, hydroxylysine, arginine, aspartic acid or glutamic acid or any other amino acid surrogate bearing a hydroxyl, amino, or carboxyl group on the side chain.

- The reaction between the carboxylic acid or amine group on the carbohydrate linker and the peptide can be promoted with the use of a coupling agent such as, 2-(1*H*-9-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU); 2-(1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU); 2-(1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU); benzotriazole-1-yl-oxy-tris(dimethylamino)phosphonium

hexafluorophosphate (BOP); benzotriazole-1-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate (PyBOP); 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDCI); *N,N'*-dicyclohexylcarbodiimide (DCC) and the like. When the N-terminal amino acid residue is an unprotected cysteine, a native ligation method can be used
5 to couple a carbohydrate moiety onto unprotected or protected form of peptides and proteins. See, Shin, Y.; Winans, KA.; Backes, BJ.; Kent SBH.; Ellman, JA.; Bertozzi, CR. J. Am. Chem. Soc. 1999, 121, 11684-11689.

Alternatively the peptide may be directly glycosylated with one or more carbohydrate moieties at the side chain hydroxyl or amino group of an amino acid,
10 which may be serine, threonine, hydroxyproline, tyrosine, lysine, proline or arginine or any other amino acid surrogate bearing a hydroxyl or amino group on the side chain. Glycosidic bond formation may be achieved through the use of OPopS™ technology (WO000/09527) in a one-pot fashion in which the final acceptor added to the reaction is a peptide containing a free hydroxyl or amino group. Enzymatic
15 glycosylation can also be used to extend the oligosaccharide structure, under conditions well known to one skilled in the art, to the sugar residue that is introduced by the methods mentioned above. In addition, enzymatic methods can be used to further modify the oligosaccharide structure, under conditions well known to one skilled in the art, into sulfated or phosphorylated forms.

20 Global deprotection of the glycoconjugate using reagents and conditions well known to one skilled in the art affords a new class of biologically active peptides whose half-lives may be determined through assays with animal tissue homogenate or plasma or commercially available enzymes known to degrade peptides such as but not limited to trypsin, chymotrypsin, alanyl aminopeptidase, lysine
25 aminopeptidase, leucine aminopeptidase and prolyl carboxypeptidase and the like. The half-lives may be measured using a variety of analytical techniques such as mass spectrometry, gas chromatography, high performance liquid chromatography, gas chromatography/mass spectrometry or liquid chromatography/mass spectrometry. By comparison of the half-life of a glycopeptide with that of the native
30 peptide from which it was derived the effect of glycoconjugation on the peptide's stability towards peptidase enzymes can be demonstrated.

Pharmaceutical Formulation And Administration

Once isolated, glycopeptides (i.e. glycosylated peptides or analogs thereof) can be put in pharmaceutically acceptable formulations, such as those described in 5 *Remington's Pharmaceutical Sciences*, 18th ed., Mack Publishing Co., Easton, PA (1990), incorporated by reference herein, and used for specific treatment of diseases and pathological conditions with little or no effect on healthy tissues. In a preferred embodiment, the composition is held within a container which includes a label stating to the effect that the composition is approved by the FDA in the United States 10 (or other equivalent labels in other countries) for treating a disease or condition described herein. Such a container will provide therapeutically effective amount of the active ingredient to be administered to a host.

The particular glycopeptides that affect the disorders or conditions of interest can be administered to a patient either by themselves, or in pharmaceutical 15 compositions where they are mixed with suitable carriers or excipient(s). In treating a patient exhibiting a disorder of interest, a therapeutically effective amount of an agent or agents such as those listed herein is administered. A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient.

20 The compounds also can be prepared as pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts include acid addition salts such as those containing hydrochloride, sulfate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, *p*-toluenesulfonate, cyclohexylsulfamate and quinate. (See e.g., PCT/US92/03736).

25 Such salts can be derived using acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, *p*-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.

30 Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free base form of the compound is first dissolved in a suitable solvent such as an aqueous or aqueous-alcohol solution, containing the appropriate

acid. The salt is then isolated by evaporating the solution. In another example, the salt is prepared by reacting the free base and acid in an organic solvent.

Carriers or excipients can be used to facilitate administration of the compound, for example, to increase the solubility of the compound. Examples of
5 carriers and excipients include calcium carbonate, calcium phosphate, various sugars or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. In addition, the molecules tested can be used to determine the structural features that enable them to act on the *ob* gene control region, and thus to select molecules useful in this invention. Those
10 skilled in the art will know how to design drugs from lead molecules, using techniques such as those disclosed in PCT publication WO 94/18959, incorporated by reference herein.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g.,
15 for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in
20 formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.

For any glycopeptide used in the method of the invention, the therapeutically
25 effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ as determined in cell culture –(i.e., the concentration of the test compound which achieves a half-maximal disruption of the protein complex, or a half-maximal inhibition of the cellular level and/or activity of a
30 complex component).- Such information can be used to more accurately determine

useful doses in humans. Levels in plasma may be measured, for example, by HPLC.

The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al., in

- 5 *The Pharmacological Basis of Therapeutics*, 1975, Ch. 1 p. 1). It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an
10 administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient.
15 A program comparable to that discussed above may be used in veterinary medicine.

Depending on the specific conditions being treated, such agents may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in *Remington's Pharmaceutical Sciences*, 18th ed., Mack Publishing Co., Easton, PA (1990). Suitable routes may include oral, rectal,
20 transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few.

- For injection, the agents of the invention may be formulated in aqueous
25 solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. Those skilled in the art can prepare injectable peptide and protein formulations as described in, *Formulation and Delivery of Proteins and Peptides: design and Development Strategies in "Formulation and Delivery of Proteins and Peptides"* Cleland, J. L. and Langer, R.
30 eds., ACS Symposium Series 567, pp1-21, American chemical Society, Washington, DC, 1994. For such transmucosal administration, penetrants appropriate to the

barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

Agents intended to be administered intracellularly may be administered using techniques well known to those of skill in the art. For example, such agents may be encapsulated into liposomes, then administered as described above. Liposomes are spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, small organic molecules may be directly administered intracellularly.

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions. The pharmaceutical compositions of the present invention may be manufactured in a

manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical formulations for parenteral administration include aqueous
5 solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.

Aqueous injection suspensions may contain substances which increase the viscosity
10 of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical preparations for oral use can be obtained by combining the
15 active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum
20 tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose,
25 concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

30 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a

plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids,
5 such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

SEQUENCE LISTING

<110> Optimer Pharmaceuticals, Inc.

5 <120> SYNTHESIS OF GLYCOPEPTIDES WITH SUPERIOR
PHARMACOKINETIC PROPERTIES

<130> 8024-012-PR2

10 <160> 1

<170> PatentIn version 3.1

<210> 1

15 <211> 6

<212> PRT

<213> UN-NATURAL

<220>

20 <221> PEPTIDE

<222> (1)..(6)

<223>

<400> 1

25 Lys Lys Arg Gly Gly Ser
1 5

Those of skill in the art will recognize that the present invention comprises

30 multiple improvements to characteristics of the glycosylated peptide including, but not limited to enhancement of stability in the presence of peptidases and proteases, thermal stability, dimmer half-life, pharmaceutical properties, bioavailability and/or plasma half-life.

Methods and materials are described herein. However, methods and

35 materials similar or equivalent to those described herein can be also used to obtain variations of the present invention. The materials, methods, and examples are illustrative only and not intended to be limiting.

EXAMPLES

Example 1

Synthesis of 1: Peptide A (SEQ. ID NO. 1: Lys-Lys-Arg-Gly-Gly-Ser)(200

5 mg, 0.05 mmol loaded peptide) was treated with carbohydrate glycolic acid B (30 mg, 0.075 mmol), O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) (28 mg, 0.075 mmol) and diisopropylethylamine (DIPEA) (19 mg, 26 µL, 0.150 mmol) in 2 mL of DMF for 90 minutes. The conjugated peptide was cleaved from the resin by treatment with 95:2.5:2.5
10 TFA:TIS:H₂O for 90 minutes. The mixture was filtered and the filtrate was concentrated under reduced pressure to give crude glycopeptide 1. MS (ES⁺) *m/z* 799 (M + 2H)²⁺ (C₆₅H₁₀₁N₁₁O₃₅) (Scheme 1).

15 **Degradation Study:** A solution of 1 (1mg) in 0.1 M, pH 7.5 potassium phosphate buffer (1 mL) was treated with 120 units of trypsin (10 µL of a 1 mg/mL solution of trypsin 12000 units/mg). A 20 µL aliquot of the sample was immediately analyzed by LCMS.


LC conditions:

Column: Waters Symmetry 300, 4.6 x 250 mm, C18, 5 micron particle size.


20 Solvent A: H₂O/0.1% TFA
Solvent B: Acetonitrile/0.1% TFA
Gradient: 15-40% B over 30 minutes; 15% B isocratic for 10 minutes

25 The initial injection was defined as "time 0" and one subsequent injection was carried out at 40 minutes. The degradation products were characterized by mass spectrometry using electrospray positive ionization (ES⁺). Product ratios were determined by integration of photodiode array (PDA) spectra. A possible degradation pathway is shown in Scheme 2 and the degradation data are summarized in Table 1.

Scheme 1



Scheme 2




Example 2

Synthesis of 2: Prepared using the procedure described in Example 1 from peptide A (SEQ ID No. 1) and carbohydrate glycolic acid C to give the crude


- 5 triphenylmethyl protected glycopeptide 2 (Scheme 3). MS (ES⁺) *m/z* 642 ($M + H + Na$)²⁺ ($C_{60}H_{84}N_{12}NaO_{18}$).

Degradation study: Compound 2 was degraded using trypsin as described in Example 1 (Scheme 4). The data are summarized in Table 1.

Scheme 3



Scheme 4


**Example 3**

Synthesis of 3: Triphenylmethyl protected glycopeptide **2** was treated with

- 5 95:2.5:2.5 TFA:TIS: H_2O for 75 minutes and the mixture was concentrated to give crude **3** (Scheme 5). MS (ES^+) m/z 510 ($\text{M} + 2\text{H}$) $^{2+}$ ($\text{C}_{41}\text{H}_{70}\text{N}_{12}\text{O}_{18}$).

Degradation Study: Compound **3** was degraded using trypsin as described in Example 1. Only the parent **3** and no degradation products were observed. The data are summarized in Table 1.


Scheme 5

Example 4**Synthesis of 4. Peptide D (Protected Peptide A: SEQ ID No. 1)(200 mg)**

5 was treated with 95:2.5:2.5 TFA:TIS:H₂O for 90 minutes. The mixture was filtered and the filtrate was concentrated under reduced pressure to leave the crude flourenylmethyloxycarbonyl (Fmoc) protected peptide 4 (Scheme 6). MS (ES⁺) *m/z* 854 (M + H)⁺ (C₄₀H₅₉N₁₁O₁₀).

10 **Degradation Study:** Compound 4 was degraded using trypsin as described in Example 1 (Scheme 7). The data are summarized in Table 1.

Scheme 6



4

Scheme 7




Table 1

Compound	Parent (%)	Deg 1	Deg 2
1 time 0	75	5	20
1 time 40	0	0	100
2 time 0	60	0	ND
2 time 40	27	67	ND
3 time 0	100	ND	ND
3 time 40	100	ND	ND
4 time 0	92	4	4
4 time 40	1	54	45

ND = not detected.

5

These data indicate different modes of enzymatic degradation for all 4 of the representative compounds. The presence of the carbohydrate moiety in 1 alters the cleavage site of trypsin as compared with 4, which is simply an fmoc-protected peptide. In the case of 4, hydrolysis occurs sequentially inward from the N-terminus.

- 10 In the case of 1, hydrolysis is initially observed between the arginine and glycine residues. After 40 minutes, the two lysine residues conjugated to the carbohydrate were still observed, illustrating a markedly different reaction pathway than was observed for 4. The results for 2 indicate a single, as yet uncharacterized product of the enzyme reaction. We believe that the product is a stable peptide conjugate containing all 6 of the amino acid residues and the carbohydrate. A slight chemical modification or isomerization has occurred. Compound 3 shows remarkable stability to trypsin. No degradation products were observed after 40 minutes.
- 15


- It is to be understood that the above description is intended to be illustrative and not restrictive. Many embodiments will be apparent to those skilled in the art upon reviewing the above description. The scope of the invention should therefore, be determined not with reference to the above description, but should instead be

ATTORNEY DOCKET NO. 8024-012-PR2

determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. The disclosures of all articles and references, including patent publications, are incorporated herein by reference.

We claim:

1. Compounds of Formula 1 and pharmaceutically acceptable salts, esters and prodrugs thereof:



5

Formula 1

where R_1 is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination;

10 R_2 is the atom or group at the anomeric position of the carbohydrate R_1 and may be O, S, NH or CH_2 ;


R_3 is a linker composed of alone or in any combination alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, heteroaryl, heteroarylalkyl, heteroarylthio, acyloxy, carboxyesters, carboxamido, 15 arylalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, cycloalkyl, acyl, alkylacylamino or acylamino groups or amino acid residues;

R_4 and R_5 , when substituted with NH_2 and CO_2H , are any natural amino acid or amino acid surrogate;

and n is any integer from 1 to about 100, but may be greater.

20

2. Compounds of Formula 2 and pharmaceutically acceptable salts, esters and prodrugs thereof:



Formula 2

where R₁ is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination;

R₂ is the atom or group at the anomeric position of the carbohydrate R₁ and

5 may be O, S, NH or CH₂;

R₃ is a linker composed of alone or in any combination alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, heteroaryl, heteroarylalkyl, heteroarylthio, acyloxy, carboxyesters, carboxamido, arylalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, cycloalkyl, acyl,


10 alkylacylamino or acylamino groups or amino acid residues;

R₇, when substituted with NH₂ and CO₂H, is any natural or synthetic peptide containing one or more amino acid residues with side chains bearing a hydroxyl or amine function such as serine, threonine, hydroxyproline, tyrosine, lysine, hydroxylysine, arginine, or any other amino acid surrogates containing a hydroxyl or

15 amine function on the side chain;

and n is any integer from 1 to about 100, but may be greater.

3. Compounds of Formula 3 and pharmaceutically acceptable salts, esters and prodrugs thereof:



20

Formula 3

where R₁ is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination;

25 R₂ is the atom or group at the anomeric position of the carbohydrate R₁ and may be O, S, NH or CH₂;

R₃ is a linker composed of alone or in any combination alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxy, aryloxy, alkylthio, arylthio, aryl,


heteroaryl, heteroarylalkyl, heteroarylthio, acyloxy, carboxyesters, carboxamido, arylalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, cycloalkyl, acyl, alkylacylamino or acylamino groups or amino acid residues;

R₄ and R₅, when substituted with NH₂ and CO₂H, are any natural amino acid

5 or amino acid surrogate;

and n is any integer from 1 to about 100, but may be greater.

4. Compounds of Formula 4 and pharmaceutically acceptable salts, esters and prodrugs thereof:



10

Formula 4

where R₁ is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination;


15 R₂ is the atom or group at the anomeric position of the carbohydrate R₁ and may be O, S, NH or CH₂;

R₃ is a linker composed of alone or in any combination alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, heteroaryl, heteroarylalkyl, heteroarylthio, acyloxy, carboxyesters, carboxamido, 20 arylalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, cycloalkyl, acyl, alkylacylamino or acylamino groups or amino acid residues;

R₇, when substituted with NH₂ and CO₂H, is any natural or synthetic peptide containing one or more amino acid residues with side chains bearing a carboxyl function such as aspartic acid or glutamic acid, or any other amino acid surrogates 25 containing a carboxyl function on the side chain;

and n is any integer from 1 to about 100, but may be greater.

5. Compounds of Formula 5 and pharmaceutically acceptable salts, esters and prodrugs thereof:



Formula 5

5 where R_1 is any carbohydrate including mono-, di-, tri-, and tetrasaccharides and larger, which may contain one or more amino sugars, deoxy sugars or sialic acid sugars in any combination;

10 R_7 , when substituted with NH_2 and CO_2H , is any natural or synthetic peptide containing one or more amino acid residues with side chains bearing a hydroxyl or
15 amine function such as serine, threonine, hydroxyproline, tyrosine, lysine, hydroxylysine, arginine, or any other amino acid surrogates containing a hydroxyl or amine function on the side chain;

and n is any integer from 1 to about 100, but may be greater.

15 6. A method for producing compounds of Formula 1, wherein said method comprises a reaction of an α -amino group of a peptide molecule with a carboxylic acid group, joined through a linker or spacer to a carbohydrate moiety to yield a glycopeptide.

20 7. A method for producing compounds of Formula 2, wherein said method comprises a reaction of an amine or hydroxyl group on a side chain of an amino acid within a peptide molecule with a carboxylic acid group, joined through a linker or spacer to a carbohydrate moiety to yield a glycopeptide.

25 8. A method for producing compounds of Formula 3, wherein said method comprises a reaction of the α -carboxyl group of a peptide molecule with an amino group, joined through a linker or spacer to a carbohydrate moiety to yield a glycopeptide.

9. A method of producing compounds of Formula 4, wherein said method comprises a reaction of a carboxyl group on a side chain of an amino acid within a peptide molecule with an amino group, joined through a linker or spacer to a
5 carbohydrate moiety to yield a glycopeptide.

10. A method of producing compounds of Formula 5, wherein said method comprises a glycosylation of a hydroxyl or amino group on a side chain of an amino acid within a peptide molecule with a carbohydrate moiety activated at the anomeric
10 position to yield a glycopeptide.

11. A method according to Claim 6 wherein the stability of the glycopeptide towards peptidase enzymes is increased relative to the peptide.

15 12. A method according to Claim 7 wherein the stability of the glycopeptide towards peptidase enzymes is increased relative to the peptide.

13. A method according to Claim 8 wherein the stability of the glycopeptide towards peptidase enzymes is increased relative to the peptide.

20 14. A method according to Claim 9 wherein stability of the glycopeptide towards peptidase enzymes is increased relative to the peptide.

25 15. A method according to Claim 10 wherein the stability of the glycopeptide towards peptidase enzymes is increased relative to the peptide.

30 16. A compound according to Claim 1 having increased stability in the presence of peptidases and proteases, thermal stability, dimer half-life, pharmaceutical properties, bioavailability and/or plasma half-life relative to a non-glycosylated analog of the compound.

17. A compound according to Claim 2 having increased stability in the presence of peptidases and proteases, thermal stability, dimer half-life, pharmaceutical properties, bioavailability and/or plasma half-life relative to a non-glycosylated analog of the compound.

5

18. A compound according to Claim 3 having increased stability in the presence of peptidases and proteases, thermal stability, dimer half-life, pharmaceutical properties, bioavailability and/or plasma half-life relative to a non-glycosylated analog of the compound.

10

19. A compound according to Claim 4 having increased stability in the presence of peptidases and proteases, thermal stability, dimer half-life, pharmaceutical properties, bioavailability and/or plasma half-life relative to a non-glycosylated analog of the compound.

15

20. A compound according to Claim 5 having increased stability in the presence of peptidases and proteases, thermal stability, dimer half-life, pharmaceutical properties, bioavailability and/or plasma half-life relative to a non-glycosylated analog of the compound.

20

ABSTRACT OF THE DISCLOSURE

The present invention relates to novel glycopeptides having improved pharmacokinetic properties, methods of preparing said novel glycopeptides, and methods to use said novel glycopeptides.

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/036551

International filing date: 01 November 2004 (01.11.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/557,631
Filing date: 30 March 2004 (30.03.2004)

Date of receipt at the International Bureau: 23 December 2004 (23.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse